Copyright Reports & Markets. All rights reserved.

Global Viral Vector and Plasmid DNA Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope of Viral Vector and Plasmid DNA
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Viral Vector and Plasmid DNA by Type
    • 1.3.1 Overview: Global Viral Vector and Plasmid DNA Market Size by Type: 2018 Versus 2022 Versus 2029
    • 1.3.2 Global Viral Vector and Plasmid DNA Consumption Value Market Share by Type in 2022
    • 1.3.3 Plasmid DNA
    • 1.3.4 Viral Vector
  • 1.4 Global Viral Vector and Plasmid DNA Market by Application
    • 1.4.1 Overview: Global Viral Vector and Plasmid DNA Market Size by Application: 2018 Versus 2022 Versus 2029
    • 1.4.2 Cancer
    • 1.4.3 Virus Infection
    • 1.4.4 Hereditary Disease
  • 1.5 Global Viral Vector and Plasmid DNA Market Size & Forecast
  • 1.6 Global Viral Vector and Plasmid DNA Market Size and Forecast by Region
    • 1.6.1 Global Viral Vector and Plasmid DNA Market Size by Region: 2018 VS 2022 VS 2029
    • 1.6.2 Global Viral Vector and Plasmid DNA Market Size by Region, (2018-2029)
    • 1.6.3 North America Viral Vector and Plasmid DNA Market Size and Prospect (2018-2029)
    • 1.6.4 Europe Viral Vector and Plasmid DNA Market Size and Prospect (2018-2029)
    • 1.6.5 Asia-Pacific Viral Vector and Plasmid DNA Market Size and Prospect (2018-2029)
    • 1.6.6 South America Viral Vector and Plasmid DNA Market Size and Prospect (2018-2029)
    • 1.6.7 Middle East and Africa Viral Vector and Plasmid DNA Market Size and Prospect (2018-2029)

2 Company Profiles

  • 2.1 Brammer Bio
    • 2.1.1 Brammer Bio Details
    • 2.1.2 Brammer Bio Major Business
    • 2.1.3 Brammer Bio Viral Vector and Plasmid DNA Product and Solutions
    • 2.1.4 Brammer Bio Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2018-2023)
    • 2.1.5 Brammer Bio Recent Developments and Future Plans
  • 2.2 Oxford BioMedica
    • 2.2.1 Oxford BioMedica Details
    • 2.2.2 Oxford BioMedica Major Business
    • 2.2.3 Oxford BioMedica Viral Vector and Plasmid DNA Product and Solutions
    • 2.2.4 Oxford BioMedica Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2018-2023)
    • 2.2.5 Oxford BioMedica Recent Developments and Future Plans
  • 2.3 Cobra Biologics
    • 2.3.1 Cobra Biologics Details
    • 2.3.2 Cobra Biologics Major Business
    • 2.3.3 Cobra Biologics Viral Vector and Plasmid DNA Product and Solutions
    • 2.3.4 Cobra Biologics Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2018-2023)
    • 2.3.5 Cobra Biologics Recent Developments and Future Plans
  • 2.4 FinVector
    • 2.4.1 FinVector Details
    • 2.4.2 FinVector Major Business
    • 2.4.3 FinVector Viral Vector and Plasmid DNA Product and Solutions
    • 2.4.4 FinVector Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2018-2023)
    • 2.4.5 FinVector Recent Developments and Future Plans
  • 2.5 Lonza
    • 2.5.1 Lonza Details
    • 2.5.2 Lonza Major Business
    • 2.5.3 Lonza Viral Vector and Plasmid DNA Product and Solutions
    • 2.5.4 Lonza Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2018-2023)
    • 2.5.5 Lonza Recent Developments and Future Plans
  • 2.6 BioReliance
    • 2.6.1 BioReliance Details
    • 2.6.2 BioReliance Major Business
    • 2.6.3 BioReliance Viral Vector and Plasmid DNA Product and Solutions
    • 2.6.4 BioReliance Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2018-2023)
    • 2.6.5 BioReliance Recent Developments and Future Plans
  • 2.7 MolMed
    • 2.7.1 MolMed Details
    • 2.7.2 MolMed Major Business
    • 2.7.3 MolMed Viral Vector and Plasmid DNA Product and Solutions
    • 2.7.4 MolMed Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2018-2023)
    • 2.7.5 MolMed Recent Developments and Future Plans
  • 2.8 FUJIFILM Diosynth Biotechnologies
    • 2.8.1 FUJIFILM Diosynth Biotechnologies Details
    • 2.8.2 FUJIFILM Diosynth Biotechnologies Major Business
    • 2.8.3 FUJIFILM Diosynth Biotechnologies Viral Vector and Plasmid DNA Product and Solutions
    • 2.8.4 FUJIFILM Diosynth Biotechnologies Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2018-2023)
    • 2.8.5 FUJIFILM Diosynth Biotechnologies Recent Developments and Future Plans
  • 2.9 UniQure
    • 2.9.1 UniQure Details
    • 2.9.2 UniQure Major Business
    • 2.9.3 UniQure Viral Vector and Plasmid DNA Product and Solutions
    • 2.9.4 UniQure Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2018-2023)
    • 2.9.5 UniQure Recent Developments and Future Plans
  • 2.10 Aldevron
    • 2.10.1 Aldevron Details
    • 2.10.2 Aldevron Major Business
    • 2.10.3 Aldevron Viral Vector and Plasmid DNA Product and Solutions
    • 2.10.4 Aldevron Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2018-2023)
    • 2.10.5 Aldevron Recent Developments and Future Plans
  • 2.11 Richter-Helm
    • 2.11.1 Richter-Helm Details
    • 2.11.2 Richter-Helm Major Business
    • 2.11.3 Richter-Helm Viral Vector and Plasmid DNA Product and Solutions
    • 2.11.4 Richter-Helm Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2018-2023)
    • 2.11.5 Richter-Helm Recent Developments and Future Plans
  • 2.12 Eurogentec
    • 2.12.1 Eurogentec Details
    • 2.12.2 Eurogentec Major Business
    • 2.12.3 Eurogentec Viral Vector and Plasmid DNA Product and Solutions
    • 2.12.4 Eurogentec Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2018-2023)
    • 2.12.5 Eurogentec Recent Developments and Future Plans
  • 2.13 OBiO Technology
    • 2.13.1 OBiO Technology Details
    • 2.13.2 OBiO Technology Major Business
    • 2.13.3 OBiO Technology Viral Vector and Plasmid DNA Product and Solutions
    • 2.13.4 OBiO Technology Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2018-2023)
    • 2.13.5 OBiO Technology Recent Developments and Future Plans
  • 2.14 Yposkesi
    • 2.14.1 Yposkesi Details
    • 2.14.2 Yposkesi Major Business
    • 2.14.3 Yposkesi Viral Vector and Plasmid DNA Product and Solutions
    • 2.14.4 Yposkesi Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2018-2023)
    • 2.14.5 Yposkesi Recent Developments and Future Plans
  • 2.15 Cell and Gene Therapy Catapult
    • 2.15.1 Cell and Gene Therapy Catapult Details
    • 2.15.2 Cell and Gene Therapy Catapult Major Business
    • 2.15.3 Cell and Gene Therapy Catapult Viral Vector and Plasmid DNA Product and Solutions
    • 2.15.4 Cell and Gene Therapy Catapult Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2018-2023)
    • 2.15.5 Cell and Gene Therapy Catapult Recent Developments and Future Plans
  • 2.16 MassBiologics
    • 2.16.1 MassBiologics Details
    • 2.16.2 MassBiologics Major Business
    • 2.16.3 MassBiologics Viral Vector and Plasmid DNA Product and Solutions
    • 2.16.4 MassBiologics Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2018-2023)
    • 2.16.5 MassBiologics Recent Developments and Future Plans
  • 2.17 Biovian
    • 2.17.1 Biovian Details
    • 2.17.2 Biovian Major Business
    • 2.17.3 Biovian Viral Vector and Plasmid DNA Product and Solutions
    • 2.17.4 Biovian Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2018-2023)
    • 2.17.5 Biovian Recent Developments and Future Plans
  • 2.18 VGXI
    • 2.18.1 VGXI Details
    • 2.18.2 VGXI Major Business
    • 2.18.3 VGXI Viral Vector and Plasmid DNA Product and Solutions
    • 2.18.4 VGXI Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2018-2023)
    • 2.18.5 VGXI Recent Developments and Future Plans
  • 2.19 Gene Synthesis
    • 2.19.1 Gene Synthesis Details
    • 2.19.2 Gene Synthesis Major Business
    • 2.19.3 Gene Synthesis Viral Vector and Plasmid DNA Product and Solutions
    • 2.19.4 Gene Synthesis Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2018-2023)
    • 2.19.5 Gene Synthesis Recent Developments and Future Plans
  • 2.20 PlasmidFactory
    • 2.20.1 PlasmidFactory Details
    • 2.20.2 PlasmidFactory Major Business
    • 2.20.3 PlasmidFactory Viral Vector and Plasmid DNA Product and Solutions
    • 2.20.4 PlasmidFactory Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2018-2023)
    • 2.20.5 PlasmidFactory Recent Developments and Future Plans
  • 2.21 Jikai Gene
    • 2.21.1 Jikai Gene Details
    • 2.21.2 Jikai Gene Major Business
    • 2.21.3 Jikai Gene Viral Vector and Plasmid DNA Product and Solutions
    • 2.21.4 Jikai Gene Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2018-2023)
    • 2.21.5 Jikai Gene Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Viral Vector and Plasmid DNA Revenue and Share by Players (2018-2023)
  • 3.2 Market Share Analysis (2022)
    • 3.2.1 Market Share of Viral Vector and Plasmid DNA by Company Revenue
    • 3.2.2 Top 3 Viral Vector and Plasmid DNA Players Market Share in 2022
    • 3.2.3 Top 6 Viral Vector and Plasmid DNA Players Market Share in 2022
  • 3.3 Viral Vector and Plasmid DNA Market: Overall Company Footprint Analysis
    • 3.3.1 Viral Vector and Plasmid DNA Market: Region Footprint
    • 3.3.2 Viral Vector and Plasmid DNA Market: Company Product Type Footprint
    • 3.3.3 Viral Vector and Plasmid DNA Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Viral Vector and Plasmid DNA Consumption Value and Market Share by Type (2018-2023)
  • 4.2 Global Viral Vector and Plasmid DNA Market Forecast by Type (2024-2029)

5 Market Size Segment by Application

  • 5.1 Global Viral Vector and Plasmid DNA Consumption Value Market Share by Application (2018-2023)
  • 5.2 Global Viral Vector and Plasmid DNA Market Forecast by Application (2024-2029)

6 North America

  • 6.1 North America Viral Vector and Plasmid DNA Consumption Value by Type (2018-2029)
  • 6.2 North America Viral Vector and Plasmid DNA Consumption Value by Application (2018-2029)
  • 6.3 North America Viral Vector and Plasmid DNA Market Size by Country
    • 6.3.1 North America Viral Vector and Plasmid DNA Consumption Value by Country (2018-2029)
    • 6.3.2 United States Viral Vector and Plasmid DNA Market Size and Forecast (2018-2029)
    • 6.3.3 Canada Viral Vector and Plasmid DNA Market Size and Forecast (2018-2029)
    • 6.3.4 Mexico Viral Vector and Plasmid DNA Market Size and Forecast (2018-2029)

7 Europe

  • 7.1 Europe Viral Vector and Plasmid DNA Consumption Value by Type (2018-2029)
  • 7.2 Europe Viral Vector and Plasmid DNA Consumption Value by Application (2018-2029)
  • 7.3 Europe Viral Vector and Plasmid DNA Market Size by Country
    • 7.3.1 Europe Viral Vector and Plasmid DNA Consumption Value by Country (2018-2029)
    • 7.3.2 Germany Viral Vector and Plasmid DNA Market Size and Forecast (2018-2029)
    • 7.3.3 France Viral Vector and Plasmid DNA Market Size and Forecast (2018-2029)
    • 7.3.4 United Kingdom Viral Vector and Plasmid DNA Market Size and Forecast (2018-2029)
    • 7.3.5 Russia Viral Vector and Plasmid DNA Market Size and Forecast (2018-2029)
    • 7.3.6 Italy Viral Vector and Plasmid DNA Market Size and Forecast (2018-2029)

8 Asia-Pacific

  • 8.1 Asia-Pacific Viral Vector and Plasmid DNA Consumption Value by Type (2018-2029)
  • 8.2 Asia-Pacific Viral Vector and Plasmid DNA Consumption Value by Application (2018-2029)
  • 8.3 Asia-Pacific Viral Vector and Plasmid DNA Market Size by Region
    • 8.3.1 Asia-Pacific Viral Vector and Plasmid DNA Consumption Value by Region (2018-2029)
    • 8.3.2 China Viral Vector and Plasmid DNA Market Size and Forecast (2018-2029)
    • 8.3.3 Japan Viral Vector and Plasmid DNA Market Size and Forecast (2018-2029)
    • 8.3.4 South Korea Viral Vector and Plasmid DNA Market Size and Forecast (2018-2029)
    • 8.3.5 India Viral Vector and Plasmid DNA Market Size and Forecast (2018-2029)
    • 8.3.6 Southeast Asia Viral Vector and Plasmid DNA Market Size and Forecast (2018-2029)
    • 8.3.7 Australia Viral Vector and Plasmid DNA Market Size and Forecast (2018-2029)

9 South America

  • 9.1 South America Viral Vector and Plasmid DNA Consumption Value by Type (2018-2029)
  • 9.2 South America Viral Vector and Plasmid DNA Consumption Value by Application (2018-2029)
  • 9.3 South America Viral Vector and Plasmid DNA Market Size by Country
    • 9.3.1 South America Viral Vector and Plasmid DNA Consumption Value by Country (2018-2029)
    • 9.3.2 Brazil Viral Vector and Plasmid DNA Market Size and Forecast (2018-2029)
    • 9.3.3 Argentina Viral Vector and Plasmid DNA Market Size and Forecast (2018-2029)

10 Middle East & Africa

  • 10.1 Middle East & Africa Viral Vector and Plasmid DNA Consumption Value by Type (2018-2029)
  • 10.2 Middle East & Africa Viral Vector and Plasmid DNA Consumption Value by Application (2018-2029)
  • 10.3 Middle East & Africa Viral Vector and Plasmid DNA Market Size by Country
    • 10.3.1 Middle East & Africa Viral Vector and Plasmid DNA Consumption Value by Country (2018-2029)
    • 10.3.2 Turkey Viral Vector and Plasmid DNA Market Size and Forecast (2018-2029)
    • 10.3.3 Saudi Arabia Viral Vector and Plasmid DNA Market Size and Forecast (2018-2029)
    • 10.3.4 UAE Viral Vector and Plasmid DNA Market Size and Forecast (2018-2029)

11 Market Dynamics

  • 11.1 Viral Vector and Plasmid DNA Market Drivers
  • 11.2 Viral Vector and Plasmid DNA Market Restraints
  • 11.3 Viral Vector and Plasmid DNA Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry
  • 11.5 Influence of COVID-19 and Russia-Ukraine War
    • 11.5.1 Influence of COVID-19
    • 11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis

  • 12.1 Viral Vector and Plasmid DNA Industry Chain
  • 12.2 Viral Vector and Plasmid DNA Upstream Analysis
  • 12.3 Viral Vector and Plasmid DNA Midstream Analysis
  • 12.4 Viral Vector and Plasmid DNA Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    Viral vectors carry genetic material into cells by exploiting the molecular mechanisms by which viruses transmit their genomes to other cells for infection.It can occur in vivo or in vitro.Plasmid carriers are plasmids artificially constructed on the basis of natural plasmids to adapt to laboratory operations.In recent years, global viral vector and plasmid DNA manufacturing has developed rapidly, with a compound growth rate of about 28% during 2018-2018.In 2018, global sales of viral vector and plasmid DNA production reached $381 million.In 2018, China accounted for about 4% of global sales.In the next five years, the production of viral vectors and plasmid DNA products in China will continue to grow rapidly.Viral vector and plasmid DNA manufacturing are mainly divided into viral vector manufacturing and plasmid DNA manufacturing, among which viral vector manufacturing accounts for the largest proportion, accounting for nearly 38% of the total market in 2018.Viral vector and plasmid DNA manufacturing is mainly used for drug development and production of cancer, genetic diseases, viral infections and other diseases, among which cancer is the main application field, accounting for 35% in 2018.The market is highly competitive.Brammer Bio, Oxford BioMedica, Cobra Biologics, FinVector and Lonza are major suppliers.They have mastered key technologies and patents, and they have a fixed customer base. They have established a monopoly in the market.Gene therapy technology innovation and clinical trials have mushroomed in recent years, and a number of gene therapy projects have been approved for marketing in the United States, the European Union, China and other countries.The target of gene therapy has also been gradually expanded from single gene genetic diseases to malignant tumors, infectious diseases, cardiovascular diseases, autoimmune diseases, metabolic diseases and other major diseases.
    According to our (Global Info Research) latest study, the global Viral Vector and Plasmid DNA market size was valued at USD 686.8 million in 2022 and is forecast to a readjusted size of USD 2249.6 million by 2029 with a CAGR of 18.5% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
    Global Viral Vector and Plasmid DNA key players include BioReliance, Oxford BioMedica, UniQure, Cobra Biologics, etc. Global top four manufacturers hold a share over 45%.
    North America is the largest market, with a share about 50%, followed by Europe, and Asia-Pacific, both have a share over 40 percent.
    In terms of product, Viral Vectors is the largest segment, with a share about 80%. And in terms of application, the largest application is Cancers, followed by Inherited Disorders, Viral Infections, etc.
    This report is a detailed and comprehensive analysis for global Viral Vector and Plasmid DNA market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
    Key Features:
    Global Viral Vector and Plasmid DNA market size and forecasts, in consumption value ($ Million), 2018-2029
    Global Viral Vector and Plasmid DNA market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
    Global Viral Vector and Plasmid DNA market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
    Global Viral Vector and Plasmid DNA market shares of main players, in revenue ($ Million), 2018-2023
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Viral Vector and Plasmid DNA
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Viral Vector and Plasmid DNA market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Brammer Bio, Oxford BioMedica, Cobra Biologics, FinVector and Lonza, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
    Market segmentation
    Viral Vector and Plasmid DNA market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Plasmid DNA
    Viral Vector
    Market segment by Application
    Cancer
    Virus Infection
    Hereditary Disease
    Market segment by players, this report covers
    Brammer Bio
    Oxford BioMedica
    Cobra Biologics
    FinVector
    Lonza
    BioReliance
    MolMed
    FUJIFILM Diosynth Biotechnologies
    UniQure
    Aldevron
    Richter-Helm
    Eurogentec
    OBiO Technology
    Yposkesi
    Cell and Gene Therapy Catapult
    MassBiologics
    Biovian
    VGXI
    Gene Synthesis
    PlasmidFactory
    Jikai Gene
    Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Viral Vector and Plasmid DNA product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Viral Vector and Plasmid DNA, with revenue, gross margin and global market share of Viral Vector and Plasmid DNA from 2018 to 2023.
    Chapter 3, the Viral Vector and Plasmid DNA competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Viral Vector and Plasmid DNA market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
    Chapter 12, the key raw materials and key suppliers, and industry chain of Viral Vector and Plasmid DNA.
    Chapter 13, to describe Viral Vector and Plasmid DNA research findings and conclusion.

    Buy now